Durvalumab

Monoclonal antibody

Also known as MEDI4736

Approvedregulatory verdict

Evidence outlook

Approved: Non-Small Cell Lung Cancer, Hepatocellular Carcinoma, Bladder Cancer, Biliary Tract Cancer, Small Cell Lung Cancer, Endometrial Cancer, Non-Muscle Invasive Bladder Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Ovarian Cancer · Phase 3Renal Cell Carcinoma · Phase 3Urothelial Carcinoma · Phase 3

Also approved (4)
US
  • Gastric or gastroesophageal junction adeno carcinoma IMFINZI in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) as neoadjuvant and adjuvant treatment, followed by single-agent IMFINZI, is indicated for the treatment of adult patients with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
Product first approved 2017FDA label
EU
  • Non-Small Cell Lung Cancer (NSCLC)Imfinzi in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by Imfinzi as monotherapy as adjuvant treatment, is indicated for the treatment of adults with resectable NSCLC at high risk of recurrence and no EGFR mutations or ALK rearrangements (for selection criteria, see section 5.1). Imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum...
Product first approved 2018EMA
JP
  • Maintenance treatment of locally-advanced, unresectable non-small cell lung cancer following definitive chemoradiation therapy
Product first approved 2018PMDA
CA
  • Locally Advanced or Metastatic Urothelial Carcinoma IMFINZI® (durvalumab for injection) is indicated for: • the treatment of patients with locally advanced or metastatic urothelial carcinoma who: - have disease progression during or following platinum-containing chemotherapy - have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy Marketing authorization with conditions was based on a promising tumour response rate and durability of response. An improvement in survival or disease-related symptoms has not been established (see 14...
Product first approved 2017Health Canada

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (71)
Biliary Tract Cancer
NCT06282575 · Jazz Pharmaceuticals
2024-07-19 – 2030-04-01 · Biliary Tract Cancer
What this study did
NCT05771480 · AstraZeneca
2023-08-16 – 2026-09-17 · Biliary Tract Cancer
What this study did
Bladder Cancer
Endometrial Cancer
NCT05255653 · Leiden University Medical Center
2021-11-11 – 2031-01-01 · Endometrial Cancer
What this study did
Hepatocellular Carcinoma
NCT07027436 · Hamilton Health Sciences Corporation
2025-11-07 – 2028-10-10 · Hepatocellular Carcinoma (HCC)
What this study did
NCT05301842 · AstraZeneca
2022-03-28 – 2027-02-26 · Hepatocellular Carcinoma
What this study did
NCT05883644 · AstraZeneca
2023-06-27 – 2026-12-30 · Advanced Hepatocellular Carcinoma
What this study did
NCT05557838 · AstraZeneca
2023-02-15 – 2026-09-30 · Hepatocellular Carcinoma
What this study did
NCT03778957 · AstraZeneca
2018-11-30 – 2026-08-31 · Hepatocellular Carcinoma
What this study did
NCT03847428 · AstraZeneca
2019-04-29 – 2026-07-27 · Hepatocellular Carcinoma
What this study did
Non-Muscle Invasive Bladder Cancer
NCT05943106 · AstraZeneca
2023-08-11 – 2027-03-31 · Non-Muscle- Invasive Bladder Cancer
What this study did
Non-Small Cell Lung Cancer
NCT06498635 · National Cancer Institute (NCI)
2025-04-01 – 2039-07-15 · Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
What this study did
NCT04465968 · National Cancer Center Hospital East
2020-09-01 – 2030-08-31 · Superior Sulcus Tumor, Non-small Cell Lung Cancer Stage IIB, Non Small Cell Lung Cancer Stage III
What this study did
NCT06284317 · ETOP IBCSG Partners Foundation
2025-01-15 – 2030-03 · Non Small Cell Lung Cancer
What this study did
NCT04092283 · National Cancer Institute (NCI)
2020-04-29 – 2028-12-31 · Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
What this study did
NCT04585490 · Stanford University
2021-08-25 – 2028-04 · Non Small Cell Lung Cancer, NSCLC, Stage III, Nsclc
What this study did
NCT05450692 · AstraZeneca
2022-09-15 – 2027-12-31 · Advanced or Metastatic Non-Small Cell Lung Cancer
What this study did
NCT03706690 · AstraZeneca
2018-11-27 – 2027-02-26 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT02453282 · AstraZeneca
2015-07-21 – 2026-12-31 · Non-Small-Cell Lung Carcinoma NSCLC
What this study did
NCT02542293 · AstraZeneca
2015-11-03 – 2026-12-31 · Non Small Cell Lung Carcinoma NSCLC
What this study did
NCT02273375 · Canadian Cancer Trials Group
2015-02-24 – 2026-09-01 · Non-Small Cell Lung Cancer
What this study did
NCT03003962 · AstraZeneca
2017-01-02 – 2026-06-30 · Non Small Cell Lung Carcinoma NSCLC
What this study did
NCT04026412 · Bristol-Myers Squibb
2019-10-08 – 2024-11-26 · Non-Small Cell Lung Cancer (NSCLC)
What this study did
NCT04642469 · AstraZeneca
2020-11-30 – 2024-01-15 · Carcinoma, Non- Small Cell Lung
What this study did
NCT04385368 · AstraZeneca
2020-07-17 – 2023-08-31 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT02454933 · AstraZeneca
2015-07-15 – 2023-06-21 · Locally Advanced or Metastatic EGFR T790M+ NSCLC
What this study did
Ovarian Cancer
Renal Cell Carcinoma
Small Cell Lung Cancer
NCT07005128 · Amgen
2025-08-18 – 2029-08-15 · Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer
What this study did
NCT06992609 · AstraZeneca
2025-09-15 – 2029-06-30 · Small Cell Lung Carcinoma
What this study did
NCT04774380 · AstraZeneca
2021-11-11 – 2025-01-02 · Extensive-stage Small Cell Lung Cancer
What this study did
Phase 2/3 (5)
Bladder Cancer
NCT06214572 · Tata Memorial Centre
2024-03-07 – 2029-07-21 · Gall Bladder Cancer
What this study did
Hepatocellular Carcinoma
NCT06904170 · UNICANCER
2025-11-14 – 2030-09 · Hepatocellular Carcinoma
What this study did
Urothelial Carcinoma
NCT04628767 · National Cancer Institute (NCI)
2021-11-12 – 2027-09-30 · Renal Pelvis and Ureter Urothelial Carcinoma
What this study did
Other / comorbidity
NCT03258554 · National Cancer Institute (NCI)
2018-04-03 – 2025-09-04 · Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Squamous Cell Carcinoma of Unknown Primary, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Lip and Oral Cavity Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
What this study did
NCT02766335 · SWOG Cancer Research Network
2014-07-31 – 2020-09 · Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
What this study did
Phase 2 (417)
Biliary Tract Cancer
NCT07938645 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
2027-01 – 2033-03 · Biliary Tract Cancer (BTC)
What this study did
NCT06490107 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2024-05-24 – 2027-12-30 · Biliary Tract Cancer
What this study did
NCT04238637 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
2019-11-01 – 2027-12 · Intrahepatic Cholangiocarcinoma
What this study did
NCT06708858 · Dai, Guanghai
2024-08-15 – 2027-07 · Advanced Biliary Tract Cancer
What this study did
NCT07679399 · Peking Union Medical College Hospital
2025-06-01 – 2027-06-01 · Biliary Tract Neoplasms Immunotherapy
What this study did
NCT05640791 · Tianjin Medical University Cancer Institute and Hospital
2023-01-12 – 2026-12-31 · Resectable Biliary Tract Cancer
What this study did
NCT05222971 · Asan Medical Center
2022-04-01 – 2026-12-30 · Biliary Tract Cancer, DNA Damage Repair Deficiency
What this study did
NCT06017297 · Georgetown University
2024-12 – 2026-11 · Borderline Resectable Carcinoma, Biliary Tract Cancer
What this study did
NCT04298008 · Seoul National University Hospital
2020-06-25 – 2025-12-31 · Bile Duct Cancer, Chemotherapy Effect
What this study did
NCT04308174 · Asan Medical Center
2020-05-20 – 2025-12-30 · Biliary Tract Neoplasms, Gallbladder Cancer, Cholangiocarcinoma
What this study did
NCT05239169 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
2022-05-23 – 2025-02-20 · Biliary Tract Cancer (CCA), Intrahepatic Cholangiocarcinoma, Hilar Cholangiocarcinoma, Distal Cholangiocarcinoma, Gall Bladder Carcinoma
What this study did
NCT03046862 · Seoul National University Hospital
2017-02-25 – 2024-12-31 · Biliary Tract Neoplasms
What this study did
NCT04298021 · Seoul National University Hospital
2020-06-25 – 2024-12-31 · Bile Duct Cancer, Chemotherapy Effect
What this study did
NCT05935579 · Peking Union Medical College Hospital
2022-12-14 – 2024-12-30 · Biliary Tract Neoplasms, Immunotherapy
What this study did
Bladder Cancer
NCT06960577 · AstraZeneca
2025-05-15 – 2028-08-30 · Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors, Methotrexate, Vinblastine, Doxorubicin, Cisplatin, Gemcitabine
What this study did
NCT07780838 · Ohio State University Comprehensive Cancer Center
2026-11-01 – 2027-12-31 · Locally Advanced Ampulla of Vater Carcinoma, Locally Advanced Biliary Tract Carcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma, Locally Advanced Gallbladder Carcinoma, Locally Advanced Intrahepatic Cholangiocarcinoma, Metastatic Ampulla of Vater Carcinoma, Metastatic Biliary Tract Carcinoma, Metastatic Extrahepatic Cholangiocarcinoma, Metastatic Gallbladder Carcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Stage III Ampulla of Vater Cancer AJCC v8, Stage III Distal Bile Duct Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Ampulla of Vater Cancer AJCC v8, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Gallbladder Cancer AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Ampulla of Vater Carcinoma, Unresectable Biliary Tract Carcinoma, Unresectable Extrahepatic Cholangiocarcinoma, Unresectable Gallbladder Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma
What this study did
NCT06591650 · Fudan University
2024-10-24 – 2027-10-30 · Gallbladder Cancer Unresectable
What this study did
NCT03768570 · Canadian Cancer Trials Group
2019-10-25 – 2027-06-30 · Bladder Cancer
What this study did
NCT03459846 · AstraZeneca
2018-03-16 – 2026-12-31 · Urinary Bladder Neoplasms
What this study did
NCT05712356 · Lisata Therapeutics, Inc.
2023-05-13 – 2026-04-05 · Cholangiocarcinoma, Gallbladder Cancer, Gallbladder Carcinoma, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Bile Duct Cancer, Gall Bladder Cancer, Gall Bladder Carcinoma
What this study did
NCT04543110 · Ottawa Hospital Research Institute
2021-01-29 – 2024-11 · Bladder Cancer
What this study did
NCT03150836 · Terence Friedlander, MD
2017-10-01 – 2024-09-01 · Bladder Cancer
What this study did
NCT03472274 · Fundacion CRIS de Investigación para Vencer el Cáncer
2018-10-25 – 2023-04-12 · Bladder Cancer
What this study did
NCT02527434 · AstraZeneca
2015-11-02 – 2023-03-28 · Urothelial Bladder Cancer, Triple-negative Breast Cancer, Pancreatic Ductal Adenocarcinoma
What this study did
NCT03702179 · Spanish Oncology Genito-Urinary Group
2018-11-19 – 2022-08-16 · Invasive Bladder Cancer
What this study did
NCT03430895 · Memorial Sloan Kettering Cancer Center
2018-01-31 – 2021-02-10 · Non-Transitional Cell Carcinoma of the Urothelial Tract, Small Cell of the Bladder, Adenocarcinoma of the Bladder, Squamous Cell Carcinoma of the Bladder, Metastatic Bladder Cancer
What this study did
NCT03234153 · Insel Gruppe AG, University Hospital Bern
2018-07-15 – 2020-05-18 · Muscle-invasive Bladder Cancer
What this study did
NCT03534492 · Spanish Oncology Genito-Urinary Group
2018-11-16 – 2020-03-16 · Bladder Cancer
What this study did
Endometrial Cancer
NCT06680739 · Vall d'Hebron Institute of Oncology
2022-12-09 – 2032-07-01 · Colorectal Cancer, Endometrial Cancer
What this study did
NCT03660826 · National Cancer Institute (NCI)
2018-09-27 – 2027-07-01 · Endometrial Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Endometrioid Adenocarcinoma, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
What this study did
NCT03015129 · Memorial Sloan Kettering Cancer Center
2017-01 – 2022-12-30 · Endometrial Cancer, Endometrial Carcinosarcoma, Endometrial Carcinoma, Endometrial Cancer Recurrent, Endometrial Carcinoma, Recurrent
What this study did
NCT03951415 · Leiden University Medical Center
2019-07-08 – 2021-08-01 · Endometrial Neoplasms, Uterine Neoplasms, Endometrium Cancer
What this study did
NCT02725489 · Mary Crowley Medical Research Center
2016-06-03 – 2020-12-02 · Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Uterine Cancer, Cervical Cancer, Endometrial Cancer
What this study did
Hepatocellular Carcinoma
NCT06492408 · Second Affiliated Hospital of Guangzhou Medical University
2024-07-01 – 2033-12-30 · Hepatic Cancer, Surgery
What this study did
NCT06999707 · Chang Gung Memorial Hospital
2025-05-22 – 2033-05-31 · HCC - Hepatocellular Carcinoma, Tremelimumab, Durvalumab, Radiotherapy
What this study did
NCT06999694 · Chang Gung Memorial Hospital
2025-05-22 – 2033-05-31 · HCC - Hepatocellular Carcinoma, Durvalumab, Tremelimumab, Proton Radiotherapy
What this study did
NCT07122089 · Center Eugene Marquis
2026-02-25 – 2030-01-02 · Hepatocellular Carcinoma Non-resectable
What this study did
NCT05451043 · AHS Cancer Control Alberta
2023-07-05 – 2029-10-01 · Pancreatic Cancer, Hepatocellular Cancer, Biliary Tract Cancer, Cholangiocarcinoma
What this study did
NCT04430452 · Mary Feng, MD
2022-02-04 – 2029-07-31 · Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8
What this study did
NCT07081633 · AstraZeneca
2025-08-05 – 2028-12-31 · Hepatocellular Carcinoma
What this study did
NCT06880523 · Canadian Cancer Trials Group
2025-10-21 – 2028-12-31 · Hepatocellular Carcinoma
What this study did
NCT04988945 · The University of Hong Kong
2020-12-01 – 2028-12-31 · HCC
What this study did
NCT05194293 · Academic and Community Cancer Research United
2023-07-01 – 2028-12-05 · Stage IB Hepatocellular Carcinoma AJCC v8, Stage II Hepatocellular Carcinoma AJCC v8, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8
What this study did
NCT06045975 · Assistance Publique - Hôpitaux de Paris
2024-03-28 – 2028-09-27 · HCC - Hepatocellular Carcinoma
What this study did
NCT07226063 · Amit Mahipal
2026-05 – 2028-08 · Hepatocellular Carcinoma, Liver Cancer
What this study did
NCT06994299 · Weill Medical College of Cornell University
2025-10-01 – 2028-07-01 · Hepatocellular Carcinoma (HCC)
What this study did
NCT05733598 · Replimune, Inc.
2024-08-01 – 2028-07-01 · Hepatocellular Carcinoma, Biliary Tract Cancer
What this study did
NCT04522544 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
2020-12-15 – 2027-12-31 · Hepatocellular Carcinoma Non-resectable, HCC
What this study did
NCT03937830 · National Cancer Institute (NCI)
2021-03-10 – 2027-12-31 · Hepatocellular Cancer, Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
What this study did
NCT06526104 · The University of Texas Health Science Center at San Antonio
2024-12-02 – 2027-12-01 · Hepatocellular Carcinoma, Cirrhosis, Liver
What this study did
Phase 1/2 (101)
Biliary Tract Cancer
NCT07269158 · Yonsei University
2025-12 – 2029-09 · Biliary Tract Neoplasms, Advanced Cancer, Immunotherapy
What this study did
NCT06548412 · M.D. Anderson Cancer Center
2025-01-22 – 2029-05-01 · Metastatic Biliary Tract Cancer
What this study did
NCT04781192 · University of Kansas Medical Center
2022-03-22 – 2026-12 · Advanced Biliary Tract Cancer
What this study did
NCT06255262 · China Medical University, China
2024-02-15 – 2025-12-31 · Biliary Tract Cancer
What this study did
NCT05327582 · Chinese PLA General Hospital
2022-04-12 – 2024-04-30 · Pancreatic Cancer, Biliary Tract Cancer
What this study did
Bladder Cancer
NCT02643303 · Ludwig Institute for Cancer Research
2016-12-28 – 2022-02-23 · Head and Neck Squamous Cell Carcinoma, Breast Cancer, Sarcoma, Merkel Cell Carcinoma, Cutaneous T-Cell Lymphoma, Melanoma, Renal Cancer, Bladder Cancer, Prostate Cancer, Testicular Cancer, Solid Tumor
What this study did
Hepatocellular Carcinoma
NCT06027086 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2024-02-12 – 2033-09-01 · Fibrolamellar Hepatocellular Carcinoma
What this study did
NCT03942328 · Mayo Clinic
2019-09-19 – 2030-08-31 · Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Hepatocellular Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma
What this study did
NCT03539822 · Anwaar Saeed
2018-10-22 – 2029-06-30 · Gastric Cancer, Esophageal Adenocarcinoma, Hepatocellular Carcinoma, Colorectal Cancer
What this study did
NCT06911255 · Yoon Jun Kim
2025-04-18 – 2028-06-30 · Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Carcinoma
What this study did
NCT06608940 · Case Comprehensive Cancer Center
2025-11 – 2028-01-01 · Hepato Cellular Carcinoma (HCC)
What this study did
NCT06111326 · Biocity Biopharmaceutics Co., Ltd.
2023-10 – 2026-05 · Hepatocellular Carcinoma
What this study did
NCT03970616 · AVEO Pharmaceuticals, Inc.
2019-09-30 – 2023-04-04 · Hepatocellular Carcinoma
What this study did
NCT04124991 · Seoul National University Hospital
2020-06-12 – 2022-07-28 · Hepatocellular Carcinoma
What this study did
Non-Muscle Invasive Bladder Cancer
NCT04106115 · University College, London
2022-03-25 – 2032-09-30 · Bladder Cancer
What this study did
Non-Small Cell Lung Cancer
NCT06694454 · National Cancer Institute (NCI)
2026-11-24 – 2034-12-31 · Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Carcinoma, Non Small Cell Lung Cancer, Non Small Cell Lung Carcinoma
What this study did
NCT03694236 · Yonsei University
2019-02-12 – 2027-05 · Potentially Resectable Stage II/IIIa NSCLC
What this study did
NCT03148327 · Jonsson Comprehensive Cancer Center
2017-10-11 – 2026-04-23 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT05451173 · Alexander Chi
2023-10-09 – 2025-12-31 · Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Non-small Cell Lung Cancer Stage I, Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage III
What this study did
NCT03581487 · M.D. Anderson Cancer Center
2019-04-01 – 2025-10-30 · Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
NCT04748419 · University of Nebraska
2021-07-15 – 2025-09-26 · Lung Cancer, Carcinoma, Non-Small Cell Lung
What this study did
NCT04646837 · Peking Union Medical College Hospital
2021-05-01 – 2025-03 · Non-small Cell Lung Cancer
What this study did
NCT04902040 · M.D. Anderson Cancer Center
2021-04-14 – 2025-02-27 · Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Merkel Cell Carcinoma, Advanced Renal Cell Carcinoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Pathologic Stage IV Merkel Cell Carcinoma AJCC v8, Stage III Bladder Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Bladder Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
NCT05267392 · Instituto Portugues de Oncologia, Francisco Gentil, Porto
2021-02-16 – 2024-01 · Non-small Cell Lung Cancer
What this study did
NCT03164772 · Ludwig Institute for Cancer Research
2017-12-20 – 2021-10-29 · Metastatic Non-small Cell Lung Cancer, NSCLC
What this study did
NCT02805660 · Mirati Therapeutics Inc.
2016-06-01 – 2019-12-20 · Advanced Cancer
What this study did
NCT02898116 · Ludwig Institute for Cancer Research
2017-05-10 – 2017-08-04 · Non-small Cell Lung Cancer, Carcinoma, NSCLC
What this study did
NCT02403271 · Pharmacyclics LLC.
2015-03 – 2017-08 · Non-Small Cell Lung Cancer, Breast Cancer, Pancreatic Cancer
What this study did
Ovarian Cancer
NCT02726997 · M.D. Anderson Cancer Center
2016-07-06 – 2027-12-31 · Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
What this study did
NCT03249142 · ARCAGY/ GINECO GROUP
2017-10-18 – 2024-12-31 · Ovarian Cancer
What this study did
NCT02963831 · Ludwig Institute for Cancer Research
2017-09-07 – 2022-06-25 · Colorectal Cancer, Ovarian Cancer, Appendiceal Cancer
What this study did
NCT03323398 · ModernaTX, Inc.
2017-08-15 – 2021-08-18 · Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Ovarian Cancer
What this study did
NCT02431559 · Ludwig Institute for Cancer Research
2015-12-02 – 2021-06-10 · Ovarian Cancer
What this study did
Renal Cell Carcinoma
NCT03308396 · Ajjai Alva, MD
2017-12-19 – 2023-12 · Advanced Kidney Cancer, Kidney Cancer, Clear Cell Renal Cell Carcinoma
What this study did
NCT02118337 · MedImmune LLC
2014-05-19 – 2020-03-17 · Select Advanced Malignancies, Kidney Cancer, Clear Cell Renal Cell Carcinoma
What this study did
Small Cell Lung Cancer
NCT06287775 · National Cancer Institute (NCI)
2025-04-08 – 2029-07-25 · Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
What this study did
NCT07174583 · IDEAYA Biosciences
2025-10-14 – 2029-07 · Small-cell Lung Cancer, Neuroendocrine Carcinomas, Solid Tumor Show to Express DLL3
What this study did
NCT04728230 · M.D. Anderson Cancer Center
2021-01-05 – 2027-12-31 · Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
NCT02734004 · AstraZeneca
2016-03-17 – 2026-09-17 · Ovarian, Breast, SCLC, Gastric Cancers
What this study did
NCT06939036 · Ariceum Therapeutics GmbH
2025-07-01 – 2025-12-31 · Small Cell Lung Cancer Extensive Stage, Merkel Cell Carcinoma
What this study did
Urothelial Carcinoma
NCT03317158 · Noah Hahn, M.D.
2017-11-21 – 2029-12-31 · Urothelial Carcinoma, Bladder Cancer
What this study did
NCT03549715 · Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
2018-12-06 – 2025-09 · Infiltrating Bladder Urothelial Carcinoma
What this study did
NCT03871036 · The Netherlands Cancer Institute
2019-05-01 – 2025-01-15 · Urothelial Carcinoma
What this study did
NCT02891161 · Monika Joshi, MD
2016-11-16 – 2022-04-27 · Urothelial Cancer
What this study did
NCT02318277 · Incyte Corporation
2015-01-05 – 2020-10-16 · Solid Tumors, Head and Neck Cancer, Lung Cancer, UC (Urothelial Cancer)
What this study did
Other / comorbidity
NCT05187338 · Second Affiliated Hospital of Guangzhou Medical University
2021-11-01 – 2035-10-30 · Lung Cancer, Liver Cancer, Colorectal Cancer, Pancreas Cancer, Ovary Cancer, Head and Neck Cancer, Breast Cancer, Gastric Cancer, Cervical Cancer, Esophageal Cancer, Sarcoma
What this study did
NCT03011814 · City of Hope Medical Center
2017-03-08 – 2030-04-14 · Folliculotropic Mycosis Fungoides, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Sezary Syndrome, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma
What this study did
NCT04538742 · AstraZeneca
2020-12-28 – 2030-01-31 · Metastatic Breast Cancer
What this study did
NCT03616886 · Jules Bordet Institute
2018-12-28 – 2028-12 · Triple Negative Breast Cancer
What this study did
Phase 1 (145)
Biliary Tract Cancer
NCT07107750 · Washington University School of Medicine
2026-03-27 – 2032-05-31 · Metastatic Biliary Tract Cancer, Metastatic Biliary Tract Carcinoma
What this study did
NCT06564623 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2025-05-27 – 2029-03 · Biliary Tract Cancers
What this study did
NCT06546969 · University of Maryland, Baltimore
2024-10-29 – 2028-12 · Biliary Tract Cancer, Cholangiocarcinoma
What this study did
NCT04900818 · I-Mab Biopharma US Limited
2021-06-29 – 2027-12 · Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer, Gastroesophageal Junction Carcinoma, Esophageal Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC)
What this study did
NCT02586987 · AstraZeneca
2015-12-28 – 2019-09-20 · Lung Cancer, Melanoma, Head and Neck Carcinoma, Gastroesophageal Cancer, Breast Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer, Biliary Tract Cancer
What this study did
Bladder Cancer
NCT06963346 · H. Lee Moffitt Cancer Center and Research Institute
2025-06-24 – 2028-04 · Bladder Cancer
What this study did
NCT02546661 · AstraZeneca
2016-12-28 – 2026-11-30 · Muscle Invasive Bladder Cancer
What this study did
NCT04073160 · Daniel George, MD
2020-06 – 2026-01 · Bladder Cancer
What this study did
NCT03773666 · Dana-Farber Cancer Institute
2019-02-20 – 2021-08-02 · Muscle Invasive Bladder Cancer
What this study did
Endometrial Cancer
NCT03277482 · Dana-Farber Cancer Institute
2018-06-01 – 2022-07-15 · Recurrent Gynecological Cancer, Metastatic Cervical Cancer, Metastatic Ovarian Cancer, Metastatic Vaginal Cancer, Metastatic Vulvar Cancer, Metastatic Endometrial Cancer, Recurrent Cervical Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Vaginal Cancer, Recurrent Vulvar Cancer, Recurrent Endometrial Cancer
What this study did
Hepatocellular Carcinoma
NCT05155189 · Zhejiang University
2022-02-21 – 2041-05 · Hepatocellular Carcinoma
What this study did
NCT06470256 · Zhiyong Huang
2024-06-01 – 2028-06-01 · Advanced Hepatocellular Carcinoma
What this study did
NCT06710223 · University of California, San Diego
2025-01-03 – 2027-12 · Hepatocellular Carcinoma
What this study did
NCT05701488 · Jiping Wang, MD, PhD
2023-04-21 – 2027-10-01 · Resectable Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Cancer
What this study did
NCT04605731 · City of Hope Medical Center
2021-08-03 – 2027-02-23 · BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
What this study did
NCT03257761 · University of Southern California
2018-02-07 – 2026-12-31 · Extrahepatic Bile Duct Adenocarcinoma, Biliary Type, Gallbladder Adenocarcinoma, Biliary Type, Metastatic Pancreatic Adenocarcinoma, Recurrent Cholangiocarcinoma, Recurrent Gallbladder Carcinoma, Recurrent Hepatocellular Carcinoma, Recurrent Intrahepatic Cholangiocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Gallbladder Cancer AJCC V7, Stage III Hepatocellular Carcinoma AJCC v7, Stage III Intrahepatic Cholangiocarcinoma AJCC v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IIIA Gallbladder Cancer AJCC v7, Stage IIIA Hepatocellular Carcinoma AJCC v7, Stage IIIB Gallbladder Cancer AJCC v7, Stage IIIB Hepatocellular Carcinoma AJCC v7, Stage IIIC Hepatocellular Carcinoma AJCC v7, Stage IV Gallbladder Cancer AJCC v7, Stage IV Hepatocellular Carcinoma AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IVA Gallbladder Cancer AJCC v7, Stage IVA Hepatocellular Carcinoma AJCC v7, Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7, Stage IVB Gallbladder Cancer AJCC v7, Stage IVB Hepatocellular Carcinoma AJCC v7, Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7, Unresectable Gallbladder Carcinoma, Unresectable Pancreatic Carcinoma
What this study did
NCT06218511 · National Cancer Institute, Naples
2022-11-22 – 2026-11 · Hepatocellular Carcinoma
What this study did
Non-Muscle Invasive Bladder Cancer
NCT03258593 · National Cancer Institute (NCI)
2018-06-07 – 2022-10-17 · Urinary Bladder Neoplasms
What this study did
Non-Small Cell Lung Cancer
NCT04550104 · University of Leeds
2021-03-17 – 2028-03 · Non Small Cell Lung Cancer
What this study did
NCT06124118 · University of Utah
2024-04-04 – 2027-11-15 · Non Small Cell Lung Cancer
What this study did
NCT04686305 · AstraZeneca
2021-03-09 – 2027-06-30 · Locally Advanced or Metastatic Non-Small Cell Lung Cancer
What this study did
NCT04612751 · AstraZeneca
2021-02-02 – 2027-05-04 · Advanced or Metastatic NSCLC
What this study did
NCT03983954 · NeoTX Therapeutics Ltd.
2019-10-10 – 2027-03-01 · ER+ Breast Cancer, Ovarian Cancer, Cervical Squamous Cell Carcinoma, Pancreatic Adenocarcinoma, Endometrial Cancer, Renal Cell Carcinoma, Urothelial Cancer, Head and Neck Squamous Cell Carcinoma, Mesothelioma, Melanoma, Hepatocellular Carcinoma, Prostate Cancer, NSCLC, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Bladder Cancer, Colorectal Cancer Metastatic, GastroEsophageal Cancer, NSCL2 Gene Mutation, Esophageal Cancer
What this study did
NCT05136846 · Ohio State University Comprehensive Cancer Center
2021-12-06 – 2026-12-31 · Locally Advanced Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
What this study did
NCT02143466 · AstraZeneca
2014-08-05 – 2026-12-31 · Advanced Non Small Cell Lung Cancer
What this study did
NCT02264678 · AstraZeneca
2014-10-31 – 2026-12-30 · Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer
What this study did
NCT03819465 · AstraZeneca
2018-12-27 – 2026-07-01 · Metastatic Non-Small Cell Lung Cancer (NSCLC)
What this study did
NCT06083454 · William Zeitler
2023-10-23 – 2026-01-09 · Non-small Cell Lung Cancer
What this study did
NCT05443971 · Mayo Clinic
2024-01-08 – 2025-12-17 · Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8
What this study did
NCT04895579 · Zhonglin Hao
2021-05-12 – 2025-11-12 · Non Small Cell Lung Cancer
What this study did
NCT03801902 · National Cancer Institute (NCI)
2019-10-28 – 2025-09-04 · Locally Advanced Lung Non-Small Cell Carcinoma, Locally Recurrent Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
What this study did
NCT03739931 · ModernaTX, Inc.
2018-11-27 – 2025-08-01 · Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma
What this study did
NCT05911308 · UNC Lineberger Comprehensive Cancer Center
2024-04-01 – 2025-02-27 · Non-Small Cell Lung Cancer
What this study did
NCT03509012 · AstraZeneca
2018-05-02 – 2025-01-08 · Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma
What this study did
NCT04287894 · The Netherlands Cancer Institute
2018-12-28 – 2024-11-04 · Stage III NSCLC
What this study did
NCT04504669 · AstraZeneca
2020-08-18 – 2024-10-07 · Clear Cell Renal Cell Cancer, Non-Small-Cell Lung Cancer, Triple Negative Breast Neoplasms, Squamous Cell Cancer of Head and Neck, Small Cell Lung Cancer, Gastroesophageal Cancer, Melanoma, Cervical Cancer, Advanced Solid Tumours
What this study did
NCT03421353 · AstraZeneca
2018-02-07 – 2024-03-28 · Advanced Solid Tumours
What this study did
NCT05848843 · M.D. Anderson Cancer Center
2023-04-25 – 2024-01-16 · Lung Cancer, Gastro-intestinal Cancer
What this study did
NCT04870112 · AstraZeneca
2021-06-28 – 2023-08-30 · Non-Small Cell Lung Cancer, Small Cell Lung Cancer
What this study did
NCT02639026 · Abramson Cancer Center at Penn Medicine
2016-01-26 – 2023-06-27 · Metastatic, Melanoma, Non Small Cell Lung Cancer (NSCLC), Breast Cancer, Pancreatic Cancer
What this study did
NCT05157542 · Juan LI, MD
2021-06-10 – 2023-06-10 · Stage III Non-small Cell Lung Cancer
What this study did
NCT02740985 · AstraZeneca
2016-06-17 – 2023-03-31 · Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC), Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC), Colorectal Carcinoma (CRC)
What this study did
NCT04348292 · Emory University
2021-01-22 – 2022-11-04 · Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
What this study did
NCT03818776 · Case Comprehensive Cancer Center
2019-08-30 – 2022-01-27 · Non-Small Cell Lung Cancer
What this study did
NCT02088112 · MedImmune LLC
2014-03-24 – 2021-03-09 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT02572687 · Eli Lilly and Company
2016-02-19 – 2021-01-13 · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma
What this study did
NCT03275597 · University of Wisconsin, Madison
2018-02-20 – 2020-07-01 · Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage IV
What this study did
NCT02000947 · MedImmune LLC
2013-10-25 – 2019-09-17 · NSCLC, Non-small Cell Lung Cancer, Lung Cancer
What this study did
Ovarian Cancer
NCT03283943 · British Columbia Cancer Agency
2018-04-01 – 2020-12-16 · Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
What this study did
NCT03430518 · Amy Tiersten
2018-05-17 – 2020-02-10 · HER2-Negative Metastatic Breast Cancer, Recurrent Ovarian Cancer
What this study did
Phase 4 (8)
Bladder Cancer
Non-Small Cell Lung Cancer
NCT06908070 · Idris Bahce
2024-12-17 – 2028-12-17 · Non-small Cell Lung Cancer Stage III
What this study did
NCT04416633 · AstraZeneca
2021-11-30 – 2023-10-27 · Unresectable Non-small Cell Lung Cancer (NSCLC)
What this study did
NCT04613284 · Shanghai Chest Hospital
2020-12-01 – 2023-08 · Lung Cancer
What this study did
NCT04356222 · Hui Bu
2020-06 – 2023-06 · Leptomeningeal Metastasis, Durvalumab
What this study did
NCT04381494 · AstraZeneca
2020-04-27 – 2022-01-27 · Unresectable Stage III NSCLC
What this study did
Other / comorbidity
NCT06031233 · Isala
2023-09-01 – 2028-12 · Oncology, Infusion Reaction
What this study did
NCT04078152 · AstraZeneca
2019-09-05 – 2024-10-31 · Solid Tumor
What this study did
Early phase / not applicable (12)
Biliary Tract Cancer
NCT07853690 · NYU Langone Health
2026-10-05 – 2028-09 · Biliary Track Cancer
What this study did
NCT06611345 · Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
2024-10-21 – 2027-03-30 · Biliary Tract Cancers (BTC)
What this study did
Endometrial Cancer
NCT04444193 · Shanghai First Maternity and Infant Hospital
2020-08-31 – 2021-05-31 · Endometrial Cancer
What this study did
Hepatocellular Carcinoma
NCT06796114 · Centre Hospitalier Universitaire de Besancon
2025-06-25 – 2030-01-31 · Hepatocellular Carcinoma
What this study did
NCT04443322 · RenJi Hospital
2020-09-19 – 2025-12-31 · Liver Carcinoma, Liver Transplant; Complications
What this study did
NCT04517227 · Fudan University
2021-07 – 2025-10 · Hepatocellular Carcinoma
What this study did
Non-Small Cell Lung Cancer
NCT06484491 · University Medical Center Groningen
2025-09-01 – 2028-10-01 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT02492867 · University of Michigan Rogel Cancer Center
2016-01-14 – 2022-04-21 · Carcinoma, Non-Small-Cell Lung
What this study did
Small Cell Lung Cancer
NCT04985851 · Shanghai Chest Hospital
2021-09-28 – 2024-12-01 · Extensive-Stage Small-Cell Lung Cancer
What this study did
Other / comorbidity
NCT07235007 · Aichi Medical University
2025-11-20 – 2030-12-31 · Extrahepatic Cholangiocarcinoma
What this study did
NCT04851132 · Chinese Academy of Medical Sciences
2021-03-11 – 2023-06 · Esophageal Squamous Cell Carcinoma
What this study did
NCT02563925 · Memorial Sloan Kettering Cancer Center
2015-09-18 – 2021-07-14 · Metastatic Breast Cancer
What this study did
Used as active comparator (20)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (13)
Biliary Tract Cancer
NCT07710885 · Taiho Pharmaceutical Co., Ltd.
2026-06-24 – 2031-12-31 · Biliary Tract Cancer
What this study did
NCT07221253 · AstraZeneca
2025-12-04 – 2029-07-31 · Biliary Tract Cancer
What this study did
NCT06467357 · AstraZeneca
2024-08-12 – 2029-05-16 · Biliary Tract Cancer
What this study did
NCT06591520 · Akeso
2024-10-20 – 2027-12 · Biliary Tract Cancer
What this study did
Non-Small Cell Lung Cancer
NCT07195695 · Boehringer Ingelheim
2026-01-16 – 2036-09-02 · Non-small Cell Lung Cancer
What this study did
NCT07361497 · Bristol-Myers Squibb
2026-03-16 – 2034-01-13 · Non-small Cell Lung Cancer (NSCLC)
What this study did
NCT06890598 · Eli Lilly and Company
2025-03-27 – 2032-02 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT07672223 · CSPC Megalith Biopharmaceutical Co.,Ltd.
2026-07-30 – 2031-11-30 · Non-small Cell Lung Cancer
What this study did
NCT05170204 · Hoffmann-La Roche
2022-11-01 – 2030-06-16 · Non-Small Cell Lung Cancer
What this study did
NCT04380636 · Merck Sharp & Dohme LLC
2020-07-06 – 2029-07-06 · Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
What this study did
NCT04513925 · Hoffmann-La Roche
2020-08-24 – 2025-07-31 · Non-small Cell Lung Cancer (NSCLC)
What this study did
Urothelial Carcinoma
NCT07720284 · AstraZeneca
2026-07-16 – 2032-11-23 · High-risk Muscle Invasive Urothelial Carcinoma
What this study did
Phase 2/3 (2)
Biliary Tract Cancer
NCT07765433 · ECOG-ACRIN Cancer Research Group
2027-01-11 – 2029-12-31 · Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma, Locally Advanced Intrahepatic Cholangiocarcinoma, Locally Advanced Unresectable Gallbladder Adenocarcinoma, Metastatic Biliary Tract Adenocarcinoma, Metastatic Extrahepatic Cholangiocarcinoma, Metastatic Gallbladder Adenocarcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Stage III Distal Bile Duct Cancer AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Biliary Tract Adenocarcinoma, Unresectable Extrahepatic Cholangiocarcinoma, Unresectable Intrahepatic Cholangiocarcinoma
What this study did
Hepatocellular Carcinoma
Phase 2 (5)
Non-Small Cell Lung Cancer
NCT06333678 · Memorial Sloan Kettering Cancer Center
2024-03-20 – 2026-01-27 · Non-Small Cell Lung Cancer
What this study did
NCT05718297 · ETOP IBCSG Partners Foundation
2024-06-07 – 2024-09-30 · NSCLC, Stage III, ALK-rearrangement
What this study did
NCT03840902 · EMD Serono Research & Development Institute, Inc.
2019-04-16 – 2023-02-17 · Non-small Cell Lung Cancer
What this study did
Small Cell Lung Cancer
NCT06773910 · SCRI Development Innovations, LLC
2025-03-11 – 2032-09 · Limited Stage Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT02794883 · Northwestern University
2016-11-01 – 2020-06-17 · Malignant Glioma, Recurrent Glioblastoma
What this study did
Appears in other studies (26)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (13)
Hepatocellular Carcinoma
NCT07166406 · NRG Oncology
2026-02-26 – 2034-03-10 · Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
What this study did
Non-Small Cell Lung Cancer
NCT07554339 · Merck Sharp & Dohme LLC
2026-06-18 – 2037-08-17 · Non-small Cell Lung Cancer
What this study did
NCT05624996 · NRG Oncology
2023-07-12 – 2036-10-15 · Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
What this study did
NCT04597671 · Association NVALT Studies
2021-12-06 – 2032-12 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT01993810 · Radiation Therapy Oncology Group
2014-01-03 – 2028-11-30 · Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7
What this study did
NCT06732401 · National Cancer Institute (NCI)
2025-08-07 – 2028-06-30 · Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
What this study did
NCT05211895 · AstraZeneca
2022-02-18 – 2027-09-08 · Non-Small Cell Lung Cancer
What this study did
Small Cell Lung Cancer
NCT07637513 · PrECOG, LLC.
2027-01 – 2038-06 · Limited Stage Small-Cell Lung Cancer
What this study did
NCT07908537 · Merck Sharp & Dohme LLC
2026-12-07 – 2036-03-10 · Small Cell Lung Cancer
What this study did
NCT06211036 · Amgen
2024-06-05 – 2030-04-02 · Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
What this study did
NCT06719336 · Anhui Shi, MD
2024-12-16 – 2028-12-16 · Extensive-stage Small Cell Lung Cancer
What this study did
Phase 2 (11)
Biliary Tract Cancer
NCT06274879 · Insel Gruppe AG, University Hospital Bern
2026-05-20 – 2030-12-30 · Bile Duct Cancer
What this study did
NCT06502080 · Shanghai Zhongshan Hospital
2024-07 – 2028-06-30 · Biliary Tract Cancer
What this study did
Non-Small Cell Lung Cancer
NCT07759492 · Intergroupe Francophone de Cancerologie Thoracique
2026-11 – 2031-02 · Non-small Cell Lung Cancer Stage III Unresectable
What this study did
NCT07603856 · University of Chicago
2026-12-12 – 2030-06-25 · Non-Small Cell Lung Cancer, Metastatic Lung Cancer
What this study did
NCT06463665 · Genelux Corporation
2024-09-26 – 2029-07 · Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma, Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent
What this study did
NCT04351256 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
2020-05-20 – 2026-01-21 · NSCLC, Stage III
What this study did
Small Cell Lung Cancer
NCT07172412 · Tianjin Medical University Cancer Institute and Hospital
2025-11 – 2028-12 · Extensive Stage Lung Small Cell Cancer
What this study did
NCT02701400 · Emory University
2016-04-14 – 2020-08-07 · Recurrent Small Cell Lung Carcinoma
What this study did
Other / comorbidity
NCT06482801 · Second Affiliated Hospital of Guangzhou Medical University
2024-06-10 – 2035-12-30 · Liver Cancer, Antibody
What this study did
NCT06483347 · Second Affiliated Hospital of Guangzhou Medical University
2024-04-04 – 2033-12-30 · Lung Cancer, Inoperable Disease
What this study did
NCT03872505 · Cedars-Sinai Medical Center
2022-07 – 2027-07 · Breast Cancer, Triple Negative Breast Cancer
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT03721679 · Oncovir, Inc.
2018-09-25 – 2021-01-26 · Solid Cancer
What this study did
Phase 1 (1)
Non-Small Cell Lung Cancer
NCT03732664 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2018-10-01 – 2023-03-23 · High-Risk Resectable NSCLC
What this study did

Competitive landscape

This mechanism is crowded: 12 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Non-Small Cell Lung Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Durvalumab: this drugApprovedMonoclonal antibodyPD-L1Reliable signal
NCT02125461: Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 13 Feb 2017 DCO; up to a maximum of approximately 3 years.): Durvalumab (MEDI4736) 16.8 Months (95% CI 13 to 18.1) vs Placebo 5.6 Months (95% CI 4.6 to 7.8)
NCT03519971: Progression-Free Survival (PFS) (Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).): Durvalumab + SoC CRT 13.8 months (95% CI 9.5 to 16.9) vs Placebo + SoC CRT 9.4 months (95% CI 7.5 to 16.6) missed
Adagrasib (Krazati)ApprovedSmall moleculeKRAS G12CPartial signalFeatured results are non-efficacy only in this race
Afatinib (Gilotrif)ApprovedSmall moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01121393: Progression-free Survival (Tumour assessment were performed at screening, week 6, 12, 18, 24, 30, 36, 42, 48 and then every 12 weeks until progression or death whichever occurs first up to week 168): Afatinib 40 Milligram (mg) 11.01 months (95% CI 9.66 to 13.73) vs Gemcitabine / Cisplatin Chemotherapy 5.59 months (95% CI 4.67 to 6.7)
NCT01523587: Progression-free Survival, Based on Central Independent Review as Determined by Response Evaluation Criteria in Solid Tumours 1.1 (First treatment administration up until cut off date of 02 March 2015 (up to 1058 days).): Afatinib 2.63 Months (95% CI 2 to 2.86) vs Erlotinib 1.94 Months (95% CI 1.87 to 2.1)
Alectinib (Alecensa)ApprovedSmall moleculeALKPartial signal
NCT02838420: Investigator-assessed progression-free survival: hazard ratio 0.22 (95% CI 0.13 to 0.38; p<0.0001), median not estimable with alectinib vs 11.1 months with crizotinib (ALESIA primary analysis, Lancet Respir Med 2019).
NCT02604342: Progression-Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator (Randomization to first documented disease progression, death from any cause, or study end (up to 33 months)): Experimental: Alectinib 10.9 months (95% CI 8.1 to 15.5) vs Active Comparator: Premetrexed/Docetaxel 1.4 months (95% CI 1.2 to 1.6)
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AmivantamabApprovedMultispecific antibodyEGFR x c-METPartial signal
NCT04487080: Progression-free survival by blinded independent central review (MARIPOSA, primary endpoint): amivantamab + lazertinib (Arm A, n=429) median 23.72 months (95% CI 19.12 to 27.66) vs osimertinib (Arm B, n=429) 16.59 months (95% CI 14.78 to 18.46); hazard ratio 0.70 (95% CI 0.58 to 0.85), log-rank p = 0.0002. ClinicalTrials.gov posted results.
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
AtezolizumabApprovedMonoclonal antibodyPD-L1Partial signal
NCT03456063: IRF-assessed EFS, stage IIB-IIIB EGFR/ALK wild-type: HR 0.77 (95% CI 0.58-1.02), log-rank p=0.0704 missed
NCT02366143: Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT Population (Baseline until disease progression or death, whichever occurs first until data cut-off on 15 September 2017 (up to approximately 29 months)): Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) — Teff-high WT Population: 11.3 Months (95% CI 9.1 to 13); ITT-WT Population: 8.3 Months (95% CI 7.7 to 9.8) vs Arm C (Bevacizumab+Paclitaxel+Carboplatin) — Teff-high WT Population: 6.8 Months (95% CI 5.9 to 7.4); ITT-WT Population: 6.8 Months (95% CI 6 to 7.1)
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-APartial signal
NCT03329911: Overall response rate at week 18: 48.0% BAT1706 vs 44.5% EU-bevacizumab; risk ratio 1.08 (90% CI 0.94 to 1.24) and risk difference 0.03 (95% CI -0.04 to 0.11), both inside the pre-specified equivalence margins (Cancer Med 2023).
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor InhibitorPartial signal
NCT00806923: Progression-free survival: HR 0.75 (95% CI 0.64-0.87; P=0.0003) for bevacizumab 7.5 mg/kg + cisplatin/gemcitabine vs placebo + cisplatin/gemcitabine, and HR 0.85 (95% CI 0.73-1.00; P=0.0456) for bevacizumab 15 mg/kg vs placebo
NCT00021060: Overall survival, paclitaxel-carboplatin plus bevacizumab (n=434) vs paclitaxel-carboplatin alone (n=444): median 12.3 vs 10.3 months, hazard ratio for death 0.79, P = 0.003 (Sandler et al., NEJM 2006).
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT01966003: Objective response rate (central independent blinded review, RECIST v1.1), ABP 215 (bevacizumab-awwb, n=328) vs bevacizumab (n=314): 39.0% vs 41.7%; risk ratio 0.93 (2-sided 90% CI 0.80 to 1.09), inside the prespecified equivalence margin of 0.67 to 1.5 (CT.gov posted results).
BinimetinibApprovedSmall moleculeMEK1/2Weak signalNo reviewed efficacy summary in this indication
BrigatinibApprovedSmall moleculeALKPartial signal
NCT03596866: Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1 (Up to 33.8 months): Brigatinib 19.253 months vs Alectinib 19.187 months missed
NCT02737501: Progression-free Survival (PFS) (Up to end of study (Up to 56 months)): Randomized Phase: Brigatinib 90 mg QD/180 QD 24.016 months (95% CI 18.46 to 43.2) vs Randomized Phase: Crizotinib 250 mg BID 11.072 months (95% CI 9.13 to 13.01)
CapmatinibApprovedSmall moleculeMETWeak signal
NCT04427072: Progression-free Survival (PFS) Per Blinded Independent Review Committee (BIRC) Using RECIST v1.1 (From randomization to the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 21 months): Capmatinib 6.1 months (95% CI 1.61 to 13.77) vs Docetaxel 4.1 months
NCT02414139: Overall response rate by independent review, single-arm cohorts: treatment-naive with MET mutation 68.3% (95% CI 55 to 79.7); pre-treated with MET mutation 44% (34.1 to 54.3); pre-treated MET copy number >= 10 29% (18.7 to 41.2); copy number < 4 6.7% (0.8 to 22.1).
CemiplimabApprovedMonoclonal antibodyPD-1Partial signal
NCT03088540: Overall Survival (OS) (Up to 94 months): Cemiplimab 23.4 months (95% CI 19.4 to 27.6) vs Chemotherapy 13.7 months (95% CI 11.2 to 16.2)
NCT03409614: Part 1: Overall Survival (OS) (Up to a maximum of 82.2 months): Part 1: Cemiplimab + Chemotherapy 15.9 months (95% CI 11.7 to 24.2) | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab 20.1 months (95% CI 13.7 to 28.3) vs Part 1: Chemotherapy 13.9 months (95% CI 10 to 17.7)
CeritinibApprovedSmall moleculeALKPartial signal
NCT01828099: Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause, up to approximately 34 months): Ceritinib 16.6 Months (95% CI 12.6 to 27.2) vs Chemotherapy 8.1 Months (95% CI 5.8 to 11.1)
NCT01828112: Progression Free Survival (PFS) Per Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause up to approximately 24 months): Ceritinib 5.4 months (95% CI 4.1 to 6.9) vs Chemotherapy 1.6 months (95% CI 1.4 to 2.8)
CrizotinibApprovedSmall moleculeALK, ROS1, MET/HGFR, and RONPartial signal
NCT01639001: Progression-Free Survival (PFS) Based on IRR by Treatment Arm (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (whichever occurred first, assessed up to 33 months)): Crizotinib 11.1 Months (95% CI 8.3 to 12.6) vs Chemotherapy 6.8 Months (95% CI 5.7 to 7)
NCT01154140: Progression-Free Survival (PFS) Based on IRR (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (up to 35 months)): Crizotinib 10.9 months (95% CI 8.3 to 13.9) | Chemotherapy 7 months (95% CI 6.8 to 8.2)
DabrafenibApprovedSmall moleculeBRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)Weak signal
NCT04452877: Objective response rate (central and investigator assessment): 75% (95% CI 50.9-91.3%). Disease control rate (central independent review): 95% (95% CI 75.1-99.9%).
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Dacomitinib PF-00299804
ApprovedUS marketing discontinued
Small moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01774721: Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review (Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)): Dacomitinib 14.7 months (95% CI 11.1 to 16.6) vs Gefitinib 9.2 months (95% CI 9.1 to 11)
NCT01000025: Overall Survival (42 Months): PF-00299804 6.83 Months (95% CI 6.08 to 7.49) vs Placebo 6.31 Months (95% CI 5.32 to 7.52) missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT04656652: Dual primaries vs docetaxel: progression-free survival 4.4 vs 3.7 months (hazard ratio 0.75; 95% CI 0.62 to 0.91; P=.004); overall survival 12.9 vs 11.8 months (hazard ratio 0.94; 95% CI 0.78 to 1.14; P=.530) (TROPION-Lung01, J Clin Oncol 2025).
NCT04484142: Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) (From baseline until disease progression, death, or other protocol defined reason, up to approximately 24 months.): Dato DXd 6.0 mg/kg Q3W 35.8% (95% CI 27.8 to 44.4)
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
EncorafenibApprovedSmall moleculeBRAF V600EWeak signal
NCT03915951: Percentage of Participants With Confirmed Objective Response (OR) as Determined by Independent Radiology Review (IRR) (From date of the first dose of study intervention until documented progressive disease (PD) or start of new anticancer therapy (up to 36 months)): Treatment-Naive 74.6% (95% CI 61.6 to 85) | Previously Treated 46.2% (95% CI 30.1 to 62.8)
Ensartinib (Ensacove)ApprovedSmall moleculeALKPartial signal
NCT02767804: eXalt3 (NCT02767804), primary endpoint PFS: ensartinib median PFS 25.8 months vs crizotinib 12.7 months; HR 0.51 (95% CI 0.35-0.72); p<.001.
EntrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
ErlotinibApprovedSmall moleculeEGFRPartial signal
NCT00446225: Primary endpoint, progression-free survival: hazard ratio 0.42 (95% CI 0.27 to 0.64), p=0.0001, erlotinib vs platinum doublet chemotherapy in EGFR-mutant NSCLC (CT.gov posted results).
GefitinibApprovedSmall moleculeEGFRPartial signal
NCT00020709: Overall survival (maintenance phase, SWOG S0023): median survival 23 months with gefitinib (n=118) vs 35 months with placebo (n=125), two-sided P=.013 missed
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)Partial signal
NCT00003589: Median overall survival: paclitaxel-cisplatin (arm A) 8.1 months vs gemcitabine-cisplatin (arm B) 8.9 months vs paclitaxel-gemcitabine (arm C) 6.7 months; response rates 31.8% / 36.6% / 27.7% respectively
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistPartial signal
NCT01285609: Median overall survival: 13.37 months with ipilimumab plus paclitaxel/carboplatin (95% CI 11.76 to 14.78) vs 12.42 months with placebo plus paclitaxel/carboplatin (95% CI 11.6 to 13.63). missed
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
LarotrectinibApprovedSmall moleculeTRK (TRKA/TRKB/TRKC, encoded by NTRK1/NTRK2/NTRK3 gene fusions)not yet gradedNo reviewed efficacy summary in this indication
LazertinibApprovedSmall moleculeEGFRPartial signal
NCT04487080: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)): Experimental: Arm A (Open-label): Amivantamab + Lazertinib 23.72 Months (95% CI 19.12 to 27.66) | Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib 18.46 Months (95% CI 14.75 to 20.11) vs Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib 16.59 Months (95% CI 14.78 to 18.46)
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
LorlatinibApprovedSmall moleculeALK / ROS1Partial signalNo reviewed efficacy summary in this indication
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00540514: Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment (Objective response was evaluated every 6 weeks until progression or new anti-cancer therapy initiation, up to 22 months.): Albumin-bound Paclitaxel + Carboplatin 33% (95% CI 28.6 to 36.7) vs Paclitaxel + Carboplatin 25% (95% CI 21.2 to 28.5)
NecitumumabApprovedMonoclonal antibodyEpidermal growth factor receptor (EGFR)Partial signal
NCT00981058: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31 Months)): Necitumumab + Gemcitabine + Cisplatin 11.5 Months (95% CI 10.4 to 12.6) vs Gemcitabine + Cisplatin 9.9 Months (95% CI 8.9 to 11.1)
NCT00982111: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31.6 Months)): Necitumumab + Pemetrexed + Cisplatin 11.3 Months (95% CI 9.5 to 13.4) vs Pemetrexed + Cisplatin 11.5 Months (95% CI 10.1 to 13.1) missed
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT01673867: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Nivolumab 12.19 Months (95% CI 9.66 to 14.98) vs Docetaxel 9.36 Months (95% CI 8.05 to 10.68)
NCT01642004: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 199 deaths, up to November 2014, approximately 25 months): Nivolumab 9.23 months (95% CI 7.33 to 13.27) vs Docetaxel 6.01 months (95% CI 5.13 to 7.33)
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Osimertinib (Tagrisso)ApprovedSmall moleculeEGFRPartial signal
NCT02151981: Progression Free Survival (PFS) by Investigator Assessment (RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).): Osimertinib 80mg 10.1 Months (95% CI 8.3 to 12.3) | Chemotherapy 4.4 Months (95% CI 4.2 to 5.6)
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02142738: Progression Free Survival (PFS) Rate at Month 6 (Month 6): Pembrolizumab 62.1% (95% CI 53.8 to 69.4) vs SOC Chemotherapy 50.3% (95% CI 41.9 to 58.2)
NCT01905657: Overall Survival (OS) (Through pre-specified database cutoff date of 30 Sep 2015 (Up to approximately 24 months)): Pembrolizumab 2 mg/kg — Strongly PD-L1 Positive: 14.9 Months; All PD-L1 Positive: 10.4 Months (95% CI 9.4 to 11.9) | Pembrolizumab 10 mg/kg — Strongly PD-L1 Positive: 17.3 Months; All PD-L1 Positive: 12.7 Months (95% CI 10 to 17.3) vs Docetaxel 75 mg/m^2 — Strongly PD-L1 Positive: 8.2 Months (95% CI 6.4 to 10.7); All PD-L1 Positive: 8.5 Months (95% CI 7.5 to 9.8)
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1Partial signalFeatured results are non-efficacy only in this race
Pemetrexed (Alimta)ApprovedSmall moleculeThymidylate synthase (TS), dihydrofolate reductase (DHFR), GARFTPartial signal
NCT00789373: Investigator-assessed Objective Progression-free Survival (PFS) (Date of randomization to the date of measured PD or date of death from any cause (up to 19.3 months)): Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed 4.11 months (95% CI 3.15 to 4.57) | Pemetrexed + Cisplatin Followed by Placebo 2.83 months (95% CI 2.6 to 3.12)
NCT00102804: Progression-Free Survival (PFS) Time (Randomization to measured PD or death from any cause (up to 41 months)): Pemetrexed and BSC 4.27 months (95% CI 4.07 to 4.73) | Placebo and BSC 2.6 months (95% CI 1.68 to 2.83)
Porfimer SodiumApprovedSmall moleculePhotoactivated radicalsWeak signalFeatured results are safety and non-efficacy only in this race
PralsetinibApprovedSmall moleculeRETPartial signal
NCT04222972: Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS) (Up to approximately 50 months): Arm B: Treatment Period- Pralsetinib 18.7 months (95% CI 11.1 to 25.2) vs Arm A: Treatment Period- SOC 9 months (95% CI 7.1 to 11.5)
NCT03037385: Phase 2 confirmed overall response rate by blinded central review (RECIST 1.1), pralsetinib 400 mg once daily, single arm: RET fusion-positive NSCLC after platinum 63.1% (95% CI 54.2 to 71.4; n=130); treatment-naive RET fusion-positive NSCLC 78.3% (95% CI 69.2 to 85.7; n=106).
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT05633602: Pragmatica-Lung (NCT05633602), primary endpoint overall survival: ramucirumab plus pembrolizumab median OS 10.1 months vs SOC 10.0 months; HR 1.04 (95% CI 0.88-1.22); p=.66. missed
NCT01168973: Overall survival: ramucirumab plus docetaxel 10.5 months vs placebo plus docetaxel 9.1 months (HR 0.86, 95% CI 0.75-0.98; p=0.023), n=1253 (Garon et al., Lancet 2014, REVEL).
RepotrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
Rybrevant Faspro (amivantamab And Hyaluronidase-Lpuj)ApprovedMultispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
Selpercatinib (Retevmo)ApprovedSmall moleculeRETPartial signal
NCT04819100: Investigator-assessed event-free survival, stage II-IIIA (primary): 2-year EFS 92% with selpercatinib vs 61% with placebo; HR 0.17 (95% CI 0.06 to 0.51), P<0.001 (Wu et al., N Engl J Med 2026)
NCT04194944: PFS by blinded independent central review (pembrolizumab-eligible population): median 24.84 months with selpercatinib (95% CI 16.89 to not estimable) vs 11.17 months with platinum-pemetrexed plus pembrolizumab (95% CI 8.77 to 16.76); HR 0.465 (95% CI 0.309 to 0.699), p=0.0002
Sevabertinib (Hyrnuo)ApprovedSmall moleculeEGFR/HER2Weak signalNo reviewed efficacy summary in this indication
SotorasibApprovedSmall moleculeKRAS G12CPartial signal
NCT04303780: Progression-free Survival (PFS) (Baseline up to primary analysis data cut-off date (02 August 2022); max time on study as of primary analysis data cut off was 24.3 months): AMG 510 5.62 months (95% CI 4.27 to 7.75) vs Docetaxel 4.47 months (95% CI 3.02 to 5.68)
NCT03600883: NSCLC cohort (FDA label section 14, single arm): objective response rate 36% (95% CI 28 to 45) by blinded independent central review in 124 patients given sotorasib 960 mg once daily; complete response 2%, partial response 35%; median duration of response 10 months (range 1.3+ to 11.1); 58% of responders had a response lasting 6 months or more.
Sunvozertinib (Zegfrovy)ApprovedSmall moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
TaletrectinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1Partial signalNo reviewed efficacy summary in this indication
Telisotuzumab VedotinApprovedAntibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
Tepotinib (Tepmetko)ApprovedSmall moleculeMETWeak signal
NCT02864992: ORR by independent review 46% (95% CI 36–57) in 99 patients with at least 9 months of follow-up; median duration of response 11.1 months
TrametinibApprovedSmall moleculeMEK1/2Partial signal
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Weak signal
NCT04644237: Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer (9 months after the last participant is randomized to data cut off, up to approximately 21 months): Trastuzumab Deruxtecan 5.4 mg/kg 50% (95% CI 39.9 to 60.1) | Trastuzumab Deruxtecan 6.4 mg/kg 56% (95% CI 41.3 to 70)
TremelimumabApprovedMonoclonal antibodyCTLA-4Partial signal
NCT02453282: Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy (From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).): Durvalumab + Tremelimumab 11.9 months (95% CI 9 to 17.7) vs Durvalumab Monotherapy 16.3 months (95% CI 12.2 to 20.8) | SoC Chemotherapy 12.9 months (95% CI 10.5 to 15) missed
NCT02352948: Overall Survival (OS) (From randomization (Day 1) until death due to any cause, approximately 36 months): Sub-study B: Durvalumab+Tremelimumab 11.5 months (95% CI 8.7 to 14.1) vs Sub-study A: Durvalumab 11.7 months (95% CI 8.2 to 17.4) | Sub-study A: SoC 6.8 months (95% CI 4.9 to 10.2) | Sub-study B: SoC 8.7 months (95% CI 6.5 to 11.7) missed
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zenocutuzumab (Bizengri)ApprovedMultispecific antibodyHER2; HER3 (blocks NRG1 binding to HER3)not yet gradedNo reviewed efficacy summary in this indication
ZidesamtinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT02364999: Objective Response Rate (ORR) by Week 19 (25 weeks): PF-06439535 45.3% (95% CI 40.01 to 50.57) vs Bevacizumab-EU 44.6% (95% CI 39.4 to 49.89)
Zongertinib (Hernexeos)ApprovedSmall moleculeHER2 Mutant-selectivenot yet gradedNo reviewed efficacy summary in this indication
7MW3711Phase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
Abp 234Phase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
AdebrelimabPhase 3Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
Aglatimagene BesadenovecPhase 3Gene therapy / editingHerpes simplex virus thymidine kinase (HSV-tk) gene productnot yet gradedNo reviewed efficacy summary in this indication
ApatinibPhase 3Small moleculeVEGFR2Partial signal
NCT01270386: Primary (PFS): median 4.7 vs 1.9 months, apatinib vs placebo, significantly improved; ORR 12.2% vs 0%; DCR 69% vs 24%.
APG-2449Phase 3Small moleculeFAK / ALK / ROS1not yet gradedNo reviewed efficacy summary in this indication
CabozantinibPhase 3Small moleculeMET / VEGFR / AXL / RET (multi-kinase)Partial signal
NCT04471428: Overall Survival (OS) (Up to approximately 24 months): Atezolizumab + Cabozantinib 10.7 months (95% CI 8.8 to 12.3) vs Docetaxel Monotherapy 10.5 months (95% CI 8.6 to 13) missed
CadonilimabPhase 3Multispecific antibodyPD-1×CTLA-4Weak signalNo reviewed efficacy summary in this indication
CamrelizumabPhase 3Monoclonal antibodyPD-1Partial signal
NCT03134872: Primary 1, BICR-assessed PFS in all treated randomized patients (interim analysis): median 11.3 vs 8.3 months, camrelizumab plus carboplatin and pemetrexed vs carboplatin and pemetrexed; HR 0.60 (95% CI 0.45 to 0.79); one-sided p=0.0001, met. Primary 2, BICR-assessed PFS in PD-L1-positive patients: no confirmatory test reported.
DostarlimabPhase 3Monoclonal antibodyPD-1Partial signal
NCT04655976: Overall Survival (OS) (Arm A Versus Arm C) (Up to approximately 234 weeks): Cobolimab + Dostarlimab + Docetaxel (Arm A) 11.9 Months (95% CI 10.6 to 14.2) vs Docetaxel (Arm C) 11.3 Months (95% CI 9.5 to 13.9) missed
EnvafolimabPhase 3Monoclonal antibodyPD-L1Weak signal
NCT05068427: Primary endpoint ORR 6.7% (2/30); DCR 50% (15/30); median PFS 3.5 months
Fetrastobart VedotinPhase 3Antibody–drug conjugatePD-L1not yet gradedNo reviewed efficacy summary in this indication
IvonescimabPhase 3Multispecific antibodyPD-1 + VEGFAReliable signal
NCT05499390: HARMONi-2 (NCT05499390), independent-review PFS at the interim analysis: ivonescimab 11.1 vs pembrolizumab 5.8 months; HR 0.51 (95% CI 0.38-0.69), one-sided p<0.0001; 398 randomized
NCT05184712: HARMONi-A (NCT05184712), independent-review PFS: ivonescimab plus chemotherapy 7.1 vs placebo plus chemotherapy 4.8 months; HR 0.46 (95% CI 0.34-0.62), P<.001
Izalontamab BrengitecanPhase 3Antibody–drug conjugateEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
NiraparibPhase 3Small moleculePARP1/2Partial signal
NCT04475939: Progression-free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) - Complete and Partial Response (CR/PR) Population (Up to 52 months): Niraparib + Pembrolizumab 5.55 Months (95% CI 4.14 to 8.28) vs Placebo + Pembrolizumab 5.55 Months (95% CI 4.21 to 7.16) missed
Nogapendekin Alfa Inbakicept (Anktiva)Phase 3Protein / enzyme therapeuticIL-15 superagonistnot yet gradedNo reviewed efficacy summary in this indication
Obrixtamig
Phase 3(overall)
Multispecific antibodyDLL3 (Delta-like ligand 3) x CD3not yet gradedNo reviewed efficacy summary in this indication
PenpulimabPhase 3Monoclonal antibodyPD-1Reliable signal
NCT03866993: Primary 1, IRRC-assessed PFS in the ITT population (final analysis): median 7.6 months (95% CI 6.8 to 9.6) penpulimab + chemotherapy vs 4.2 months (95% CI 4.2 to 4.3) placebo + chemotherapy; HR 0.43 (95% CI 0.33 to 0.56); p<0.0001, met. Primary 2, IRRC-assessed PFS in the PD-L1-positive subgroup: median 8.1 vs 4.2 months; HR 0.37 (95% CI 0.27 to 0.52); p<0.0001, met.
PF-08634404Phase 3Multispecific antibodyPD-1 + VEGFnot yet gradedNo reviewed efficacy summary in this indication
PumitamigPhase 3Multispecific antibodyPD-L1 and VEGF-Anot yet gradedNo reviewed efficacy summary in this indication
RilvegostomigPhase 3Multispecific antibodyPD-1 and TIGITnot yet gradedNo reviewed efficacy summary in this indication
Risvutatug RezetecanPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
Sacituzumab GovitecanPhase 3Antibody–drug conjugateTROP2Partial signal
NCT05089734: EVOKE-01 (NCT05089734), primary endpoint overall survival: sacituzumab govitecan 11.1 months vs docetaxel 9.8 months; not statistically significant missed
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2Partial signal
NCT05870319: OptiTROP-Lung04 (NCT05870319), primary endpoint median PFS: sacituzumab tirumotecan 8.3 months vs chemotherapy 4.3 months; HR 0.49; p<0.0001
Savolitinib (Orpathys)Phase 3Small moleculeMETPartial signal
NCT05261399: SAFFRON (NCT05261399): osimertinib plus savolitinib showed a statistically significant and clinically meaningful improvement in both PFS and OS vs platinum-based doublet chemotherapy in EGFRm NSCLC patients who progressed on osimertinib.
NCT05015608: Median PFS (SACHI trial, ITT): 8.2 months savolitinib+osimertinib vs 4.5 months chemotherapy; in patients prior on 1st/2nd-gen EGFR-TKI: 9.8 vs 5.4 months; predefined significance thresholds met in both populations
SerplulimabPhase 3Monoclonal antibodyPD-1Weak signal
NCT04033354: At the final analysis, serplulimab plus chemotherapy significantly improved median OS compared to placebo plus chemotherapy (HR 0.73, 95% CI 0.58-0.93; p=0.010); at the second interim analysis, the PFS benefit was maintained in the serplulimab-chemotherapy group (HR 0.53, 95% CI 0.42-0.67).
NCT03952403: Final analysis in nonsquamous NSCLC: median overall survival reached 26.8 months for Hetronifly (serplulimab) plus chemotherapy compared with 20.3 months for chemotherapy alone, a 34% reduction in the risk of death (HR=0.66, 95% CI: 0.52-0.83, P<0.001); median PFS was 11.0 months in Group B versus 5.7 months in the chemotherapy-only arm. No statistical difference was observed for Group A compared to Group B (HR=1.12, p=0.3628).
Sotiburafusp AlfaPhase 3Multispecific antibodyPD-L1 / VEGFnot yet gradedNo reviewed efficacy summary in this indication
Sugemalimab (Cejemly)Phase 3Monoclonal antibodyPD-L1Reliable signal
NCT03728556: Progression-free survival (BICR-assessed), GEMSTONE-301: median PFS 10.5 months (sugemalimab) vs 6.2 months (placebo); HR 0.65, 95% CI 0.50-0.84
NCT03789604: Sugemalimab plus chemotherapy improved investigator-assessed PFS at interim analysis: median 7.8 vs 4.9 months, stratified HR 0.50.
TislelizumabPhase 3Monoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
Trastuzumab BrengitecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
BudigalimabPhase 2/3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
HLX43Phase 2/3Antibody–drug conjugatePD-L1not yet gradedNo reviewed efficacy summary in this indication
AL8326Phase 2Small moleculeAurora B / FGFR / VEGFR (multi-kinase)not yet gradedNo reviewed efficacy summary in this indication
Disitamab VedotinPhase 2Antibody–drug conjugateHER2Weak signalNo reviewed efficacy summary in this indication
Erdafitinib (Balversa)Phase 2Small moleculeFGFR1-4Weak signal
NCT02699606: NSCLC cohort (n=12): objective response rate 0% (no CR or PR); disease control rate 25.0% (95% CI 5.5-57.2%); 3 patients stable disease, 2 with tumor shrinkage >20%. missed
Ifinatamab DeruxtecanPhase 2Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
JS207Phase 2Multispecific antibodyPD-1 + VEGFAnot yet gradedNo reviewed efficacy summary in this indication
Notiretatug RezetecanPhase 2Antibody–drug conjugateNectin-4not yet gradedNo reviewed efficacy summary in this indication
Olvimulogene NanivacirepvecPhase 2Oncolytic virusNo discrete molecular targetnot yet gradedNo reviewed efficacy summary in this indication
Raludotatug DeruxtecanPhase 2Antibody–drug conjugateCDH6 (Cadherin-6)not yet gradedNo reviewed efficacy summary in this indication
Rinatabart Sesutecan (Rina-S)Phase 2Antibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication
TagitanlimabPhase 2Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
TUB-040Phase 2Antibody–drug conjugateNaPi2b (sodium-dependent phosphate transporter, SLC34A2)not yet gradedNo reviewed efficacy summary in this indication
UbamatamabPhase 2Monoclonal antibodyMUC16 x CD3not yet gradedNo reviewed efficacy summary in this indication
VisugromabPhase 2Monoclonal antibodyGDF-15not yet gradedNo reviewed efficacy summary in this indication
ZanidatamabPhase 2Multispecific antibodyHER2not yet gradedNo reviewed efficacy summary in this indication
ZanzalintinibPhase 2Small moleculeVEGFR2; MET; AXL; MER; TYRO3not yet gradedNo reviewed efficacy summary in this indication
BGB-B2033Phase 1/2Multispecific antibodyGPC3 (glypican-3) x 4-1BB (CD137)not yet gradedNo reviewed efficacy summary in this indication
CetrelimabPhase 1/2Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Enfortumab VedotinPhase 1/2Antibody–drug conjugateNectin-4not yet gradedNo reviewed efficacy summary in this indication
GI-101APhase 1/2Protein / enzyme therapeuticCTLA-4 / IL-2Rβγnot yet gradedNo reviewed efficacy summary in this indication
NilvanstomigPhase 1/2Biologic (subtype unspecified)PD-1 and TIGITnot yet gradedNo reviewed efficacy summary in this indication
Puxitatug SamrotecanPhase 1/2Antibody–drug conjugateB7-H4not yet gradedNo reviewed efficacy summary in this indication
Quaratusugene Ozeplasmid (Reqorsa)Phase 1/2Gene therapy / editingTUSC2 (tumor suppressor gene replacement)not yet gradedNo reviewed efficacy summary in this indication
RezatapoptPhase 1/2Small moleculep53 reactivatornot yet gradedNo reviewed efficacy summary in this indication
Tambotatug PelitecanPhase 1/2Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
TuvutromstatPhase 1/2Small moleculeMAT2AWeak signalNo reviewed efficacy summary in this indication
177Lu-RAD204Phase 1RadiopharmaceuticalPD-L1not yet gradedNo reviewed efficacy summary in this indication
ABBV-324Phase 1Antibody–drug conjugateGlypican-3 (GPC3) / Topoisomerase Inot yet gradedNo reviewed efficacy summary in this indication
AKY-1189Phase 1RadiopharmaceuticalNectin-4 (PVRL4)not yet gradedNo reviewed efficacy summary in this indication
BPI-371153Phase 1Small moleculePD-L1not yet gradedNo reviewed efficacy summary in this indication
CRX100Phase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication
IBC-Ab002
Phase 1(overall)
Monoclonal antibodyPD-L1
Partial signal(overall)
No reviewed efficacy summary in this indication
Ixotatug VedotinPhase 1Antibody–drug conjugateClaudin 6 (CLDN6)not yet gradedNo reviewed efficacy summary in this indication
LY4052031Phase 1Antibody–drug conjugateNectin-4not yet gradedNo reviewed efficacy summary in this indication
Sofetabart MipitecanPhase 1Antibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 126 furthest-along competitors are listed; 485 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(204 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Durvalumab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (32)
November 2026 (6)
Phase 1/2Esophageal Adenocarcinoma, Gastroesophageal Junction AdenocarcinomaActive not recruiting
Est. primary completion 2026-11 · NCT02962063 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-11 · NCT05856695 · CT.gov ↗
What to watch
Phase 2Germ Cell Tumor, Nonseminomatous Germ Cell Tumor, Seminoma, Germinomatous Germ Cell Tumor, Dysgerminoma, Pineal Germ Cell TumorActive not recruiting
Est. primary completion 2026-11 · NCT03158064 · CT.gov ↗
What to watch
Phase 1Locally Advanced Intrahepatic Cholangiocarcinoma, Oligometastatic Intrahepatic Cholangiocarcinoma …Recruiting
Est. primary completion 2026-11-30 · NCT06058663 · CT.gov ↗
What to watch
Phase 2Gastrointestinal Neuroendocrine CarcinomaRecruiting
Est. primary completion 2026-11-30 · NCT06070740 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2026-11-30 · NCT07081633 · CT.gov ↗
What to watch
December 2026 (26)
Phase 1Breast CancerActive not recruiting
Est. primary completion 2026-12 · NCT02826434 · CT.gov ↗
What to watch
Phase 1Biliary Tract CancerRecruiting
Est. primary completion 2026-12 · NCT04900818 · CT.gov ↗
What to watch
Phase 1/2Metastatic Pancreatic CancerActive not recruiting
Est. primary completion 2026-12 · NCT05927142 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12 · NCT05000710 · CT.gov ↗
What to watch
Phase 2Breast Neoplasm, Triple Negative Breast Cancer (TNBC), HRDRecruiting
Est. primary completion 2026-12 · NCT03740893 · CT.gov ↗
What to watch
Phase 2Stomach Cancer, AdenocarcinomaRecruiting
Est. primary completion 2026-12 · NCT05620628 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12 · NCT03965468 · CT.gov ↗
What to watch
Phase 3Oropharyngeal CancerActive not recruiting
Est. primary completion 2026-12 · NCT04116047 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12 · NCT04585490 · CT.gov ↗
What to watch
Phase 2Bile Duct Cancer, Cholangiocarcinoma, Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic …Recruiting
Est. primary completion 2026-12-01 · NCT05655949 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12-07 · NCT04245514 · CT.gov ↗
What to watch
Phase 4Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-17 · NCT06908070 · CT.gov ↗
What to watch
Phase 2Biliary Tract CancerActive not recruiting
Est. primary completion 2026-12-30 · NCT06490107 · CT.gov ↗
What to watch
Phase 2Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast CarcinomaRecruiting
Est. primary completion 2026-12-30 · NCT03606967 · CT.gov ↗
What to watch
Phase 1Solid Tumor, AdultRecruiting
Est. primary completion 2026-12-31 · NCT03772561 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-31 · NCT05136846 · CT.gov ↗
What to watch
Phase 1Primary Central Nervous System LymphomaActive not recruiting
Est. primary completion 2026-12-31 · NCT04462328 · CT.gov ↗
What to watch
Phase 1/2Breast NeoplasmsActive not recruiting
Est. primary completion 2026-12-31 · NCT03594396 · CT.gov ↗
What to watch
Phase 2Pulmonary Large-cell Neuroendocrine CarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT06418087 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT05844046 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT04602533 · CT.gov ↗
What to watch
Phase 2Anal Cancer, Anal Carcinoma, Anal Cancer Stage III, Anal Cancer Stage IIActive not recruiting
Est. primary completion 2026-12-31 · NCT04230759 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2026-12-31 · NCT03937830 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT06698250 · CT.gov ↗
What to watch
Phase 2Ovarian CancerRecruiting
Est. primary completion 2026-12-31 · NCT04918186 · CT.gov ↗
What to watch
Phase 3CancerEnrolling by invitation
Est. primary completion 2026-12-31 · NCT05303532 · CT.gov ↗
What to watch
2027 (81)
January 2027 (9)
Phase 1Solid Tumor, Adult, Malignant Solid Tumor, Stomach Adenocarcinoma, Esophageal AdenocarcinomaRecruiting
Est. primary completion 2027-01 · NCT06824363 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-01 · NCT05206812 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-01 · NCT04699838 · CT.gov ↗
What to watch
Phase 2Extrahepatic Cholangiocarcinoma, Unresectable Perihilar or Ductal CCARecruiting
Est. primary completion 2027-01 · NCT06440993 · CT.gov ↗
What to watch
Phase 2Biliary Tract CancerRecruiting
Est. primary completion 2027-01-01 · NCT07679399 · CT.gov ↗
What to watch
Phase 2Esophagus AdenocarcinomaActive not recruiting
Est. primary completion 2027-01-01 · NCT05713838 · CT.gov ↗
What to watch
Phase 2Mismatch Repair Proficient Colorectal Cancer, Pancreatic Adenocarcinoma, LeiomyosarcomaActive not recruiting
Est. primary completion 2027-01-01 · NCT03851614 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-01-18 · NCT05374603 · CT.gov ↗
What to watch
Phase 2Bladder CancerActive not recruiting
Est. primary completion 2027-01-31 · NCT03601455 · CT.gov ↗
What to watch
February 2027 (4)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-02 · NCT04499053 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-02 · NCT04716946 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-02 · NCT05696782 · CT.gov ↗
What to watch
Phase 1Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2027-02-23 · NCT04605731 · CT.gov ↗
What to watch
March 2027 (6)
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2027-03 · NCT06223711 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-03-01 · NCT03983954 · CT.gov ↗
What to watch
Phase 1/2Bladder CancerRecruiting
Est. primary completion 2027-03-30 · NCT04106115 · CT.gov ↗
What to watch
Phase 2Intrahepatic CholangiocarcinomaRecruiting
Est. primary completion 2027-03-30 · NCT05422690 · CT.gov ↗
What to watch
Phase 1Advanced Malignant Skin Neoplasm, Metastatic Malignant Skin NeoplasmActive not recruiting
Est. primary completion 2027-03-31 · NCT04387084 · CT.gov ↗
What to watch
Phase 2Bladder CancerActive not recruiting
Est. primary completion 2027-03-31 · NCT03768570 · CT.gov ↗
What to watch
April 2027 (1)
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-04 · NCT07175441 · CT.gov ↗
What to watch
May 2027 (8)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-05 · NCT03694236 · CT.gov ↗
What to watch
Phase 2Colorectal Cancer, Resectable Colorectal CarcinomaRecruiting
Est. primary completion 2027-05 · NCT05845450 · CT.gov ↗
What to watch
Phase 2Intrahepatic CholangiocarcinomaRecruiting
Est. primary completion 2027-05 · NCT06375915 · CT.gov ↗
What to watch
Phase 2Combined Hepatocellular and CholangiocarcinomaNot yet recruiting
Est. primary completion 2027-05 · NCT06855225 · CT.gov ↗
What to watch
Phase 1/2Biliary Tract CancerRecruiting
Est. primary completion 2027-05-01 · NCT06548412 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2027-05-01 · NCT05451043 · CT.gov ↗
What to watch
Phase 2Gastric CancerActive not recruiting
Est. primary completion 2027-05-04 · NCT04379596 · CT.gov ↗
What to watch
Phase 1/2Lung CancerRecruiting
Est. primary completion 2027-05-30 · NCT05886439 · CT.gov ↗
What to watch
June 2027 (11)
Phase 1Gastroesophageal AdenocarcinomaRecruiting
Est. primary completion 2027-06 · NCT05733689 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-06 · NCT05742607 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2027-06 · NCT05063565 · CT.gov ↗
What to watch
Phase 1Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-06-01 · NCT06470256 · CT.gov ↗
What to watch
Phase 1Borderline Resectable Pancreatic Ductal Adenocarcinoma, Locally Advanced Cholangiocarcinoma, Locally Advanced Pancreatic Adenocarcinoma …Recruiting
Est. primary completion 2027-06-01 · NCT07619313 · CT.gov ↗
What to watch
Phase 2Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid NeoplasmRecruiting
Est. primary completion 2027-06-01 · NCT03907475 · CT.gov ↗
What to watch
Early phase / not applicableHepatocellular CarcinomaRecruiting
Est. primary completion 2027-06-25 · NCT06796114 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-06-30 · NCT04686305 · CT.gov ↗
What to watch
Phase 2Metastatic Angiosarcoma, Metastatic Dedifferentiated Liposarcoma, Metastatic Osteosarcoma, Recurrent Angiosarcoma …Active not recruiting
Est. primary completion 2027-06-30 · NCT04668300 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-06-30 · NCT05198830 · CT.gov ↗
What to watch
Phase 3Esophageal Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2027-06-30 · NCT04550260 · CT.gov ↗
What to watch
July 2027 (5)
Phase 2Intrahepatic Cholangiocarcinoma, FGFR2 Gene Rearrangement, FGFR2 Gene MutationRecruiting
Est. primary completion 2027-07 · NCT06728410 · CT.gov ↗
What to watch
Phase 3Breast CancerRecruiting
Est. primary completion 2027-07-28 · NCT06103864 · CT.gov ↗
What to watch
Phase 2Esophageal CancerRecruiting
Est. primary completion 2027-07-31 · NCT06290505 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2027-07-31 · NCT04522544 · CT.gov ↗
What to watch
Phase 2Bladder CancerRecruiting
Est. primary completion 2027-07-31 · NCT06263153 · CT.gov ↗
What to watch
August 2027 (4)
Phase 2Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2027-08-01 · NCT07511504 · CT.gov ↗
What to watch
Phase 2ImmunotherapyActive not recruiting
Est. primary completion 2027-08-10 · NCT04169841 · CT.gov ↗
What to watch
Phase 1Solid TumoursRecruiting
Est. primary completion 2027-08-30 · NCT07391670 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-08-31 · NCT04465968 · CT.gov ↗
What to watch
September 2027 (9)
Phase 1/2Pancreatic AdenocarcinomaActive not recruiting
Est. primary completion 2027-09 · NCT03245541 · CT.gov ↗
What to watch
Phase 2Cancer, Tumors, Neoplasm, NeoplasiaRecruiting
Est. primary completion 2027-09 · NCT02925234 · CT.gov ↗
What to watch
Early phase / not applicableBiliary Tract CancerRecruiting
Est. primary completion 2027-09 · NCT07853690 · CT.gov ↗
What to watch
Phase 3Breast CancerActive not recruiting
Est. primary completion 2027-09-01 · NCT05629585 · CT.gov ↗
What to watch
Phase 1/2Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 MutationActive not recruiting
Est. primary completion 2027-09-13 · NCT06501625 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2027-09-27 · NCT06045975 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-09-30 · NCT05796089 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-09-30 · NCT04397003 · CT.gov ↗
What to watch
Phase 2/3Urothelial CarcinomaRecruiting
Est. primary completion 2027-09-30 · NCT04628767 · CT.gov ↗
What to watch
October 2027 (7)
Phase 1Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2027-10-01 · NCT05701488 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-10-01 · NCT06526104 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2027-10-01 · NCT05068232 · CT.gov ↗
What to watch
Early phase / not applicableNon-Small Cell Lung CancerRecruiting
Est. primary completion 2027-10-01 · NCT06484491 · CT.gov ↗
What to watch
Phase 3Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-10-12 · NCT07027436 · CT.gov ↗
What to watch
Phase 1/2Colorectal Neoplasms, Breast NeoplasmsActive not recruiting
Est. primary completion 2027-10-30 · NCT02484404 · CT.gov ↗
What to watch
Phase 2Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma, Stage IA Pancreatic Cancer AJCC v8 …Active not recruiting
Est. primary completion 2027-10-30 · NCT04940286 · CT.gov ↗
What to watch
November 2027 (1)
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-11-01 · NCT05687266 · CT.gov ↗
What to watch
December 2027 (16)
Phase 1Biliary Tract CancerRecruiting
Est. primary completion 2027-12 · NCT06546969 · CT.gov ↗
What to watch
Phase 1Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2027-12 · NCT06710223 · CT.gov ↗
What to watch
Phase 2Triple Negative Breast Cancer MetastaticRecruiting
Est. primary completion 2027-12 · NCT05582538 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-12 · NCT04472949 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-12-01 · NCT05733598 · CT.gov ↗
What to watch
Phase 2Invasive Breast Cancer, Inflammatory Breast Cancer Stage III, HER2-positive Breast Cancer, HER2 Low Breast Adenocarcinoma, Breast CancerRecruiting
Est. primary completion 2027-12-01 · NCT05795101 · CT.gov ↗
What to watch
Phase 2Gastric Adenocarcinoma, Malignant MelanomaActive not recruiting
Est. primary completion 2027-12-01 · NCT03780608 · CT.gov ↗
What to watch
Phase 2Bladder CancerRecruiting
Est. primary completion 2027-12-22 · NCT06503614 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12-30 · NCT04585477 · CT.gov ↗
What to watch
Phase 1Urothelial CarcinomaActive not recruiting
Est. primary completion 2027-12-31 · NCT02812420 · CT.gov ↗
What to watch
Phase 1/2Ovarian CancerActive not recruiting
Est. primary completion 2027-12-31 · NCT02726997 · CT.gov ↗
What to watch
Phase 1/2Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-12-31 · NCT04728230 · CT.gov ↗
What to watch
Phase 2Rare TumourNot yet recruiting
Est. primary completion 2027-12-31 · NCT06692491 · CT.gov ↗
What to watch
Phase 2Lung CancerRecruiting
Est. primary completion 2027-12-31 · NCT05632809 · CT.gov ↗
What to watch
Phase 2Bladder CancerRecruiting
Est. primary completion 2027-12-31 · NCT07780838 · CT.gov ↗
What to watch
Early phase / not applicableExtrahepatic CholangiocarcinomaRecruiting
Est. primary completion 2027-12-31 · NCT07235007 · CT.gov ↗
What to watch
2028 (43)
January 2028 (5)
Phase 2Malignant Solid NeoplasmsRecruiting
Est. primary completion 2028-01 · NCT02029001 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-01 · NCT04105270 · CT.gov ↗
What to watch
Phase 2Ovarian CancerRecruiting
Est. primary completion 2028-01 · NCT04644289 · CT.gov ↗
What to watch
Phase 2Extrapulmonary Small Cell CarcinomaRecruiting
Est. primary completion 2028-01-01 · NCT06464068 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2028-01-31 · NCT06880523 · CT.gov ↗
What to watch
February 2028 (3)
Phase 2Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2028-02 · NCT07226063 · CT.gov ↗
What to watch
Phase 2Triple Negative Breast CancerRecruiting
Est. primary completion 2028-02 · NCT06954480 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-02-24 · NCT05617963 · CT.gov ↗
What to watch
March 2028 (4)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-03-01 · NCT07653438 · CT.gov ↗
What to watch
Phase 1/2Hepatocellular CarcinomaRecruiting
Est. primary completion 2028-03-31 · NCT06911255 · CT.gov ↗
What to watch
Phase 2Gastric Adenocarcinoma, Gastroesophageal Junction AdenocarcinomaActive not recruiting
Est. primary completion 2028-03-31 · NCT05034887 · CT.gov ↗
What to watch
Phase 2Renal Cell CarcinomaActive not recruiting
Est. primary completion 2028-03-31 · NCT03682289 · CT.gov ↗
What to watch
April 2028 (2)
Phase 1Bladder CancerRecruiting
Est. primary completion 2028-04 · NCT06963346 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-04 · NCT07146230 · CT.gov ↗
What to watch
May 2028 (2)
Phase 1Small Cell Lung CancerRecruiting
Est. primary completion 2028-05-21 · NCT07531095 · CT.gov ↗
What to watch
Phase 1/2MesotheliomaRecruiting
Est. primary completion 2028-05-31 · NCT05932199 · CT.gov ↗
What to watch
June 2028 (2)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-06 · NCT06680050 · CT.gov ↗
What to watch
Phase 1/2Hepatocellular CarcinomaRecruiting
Est. primary completion 2028-06-30 · NCT03539822 · CT.gov ↗
What to watch
July 2028 (3)
Phase 4Oncology, Infusion ReactionRecruiting
Est. primary completion 2028-07 · NCT06031233 · CT.gov ↗
What to watch
Phase 2CholangiocarcinomaRecruiting
Est. primary completion 2028-07-01 · NCT07673341 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2028-07-31 · NCT04430452 · CT.gov ↗
What to watch
August 2028 (2)
Phase 2Bladder CancerRecruiting
Est. primary completion 2028-08-30 · NCT06960577 · CT.gov ↗
What to watch
Phase 2Bladder CancerActive not recruiting
Est. primary completion 2028-08-31 · NCT05137262 · CT.gov ↗
What to watch
September 2028 (3)
Phase 2Large Cell Neuroendocrine Carcinoma of the LungRecruiting
Est. primary completion 2028-09 · NCT06393816 · CT.gov ↗
What to watch
Phase 2Resectable Gasrtic CancerNot yet recruiting
Est. primary completion 2028-09 · NCT07757191 · CT.gov ↗
What to watch
Phase 1/2Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2028-09-01 · NCT06027086 · CT.gov ↗
What to watch
October 2028 (4)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-10-08 · NCT07288034 · CT.gov ↗
What to watch
Phase 1NeoplasmsRecruiting
Est. primary completion 2028-10-16 · NCT06551142 · CT.gov ↗
What to watch
Phase 2Stomach NeoplasmsRecruiting
Est. primary completion 2028-10-30 · NCT06630130 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-10-31 · NCT03833154 · CT.gov ↗
What to watch
November 2028 (4)
Phase 2Advanced Biliary Tract CarcinomaRecruiting
Est. primary completion 2028-11 · NCT07036380 · CT.gov ↗
What to watch
Phase 2Advanced Intrahepatic CholangiocarcinomaRecruiting
Est. primary completion 2028-11-19 · NCT06858735 · CT.gov ↗
What to watch
Phase 3Breast CancerActive not recruiting
Est. primary completion 2028-11-20 · NCT06112379 · CT.gov ↗
What to watch
Phase 3Endometrial CancerActive not recruiting
Est. primary completion 2028-11-30 · NCT06746116 · CT.gov ↗
What to watch
December 2028 (9)
Phase 3Biliary Tract CancerRecruiting
Est. primary completion 2028-12-01 · NCT06282575 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-12-16 · NCT07941609 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2028-12-30 · NCT06492408 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-12-30 · NCT06492421 · CT.gov ↗
What to watch
Phase 1/2Bladder CancerActive not recruiting
Est. primary completion 2028-12-31 · NCT03317158 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2028-12-31 · NCT06769126 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2028-12-31 · NCT04988945 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-12-31 · NCT06667908 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-12-31 · NCT04092283 · CT.gov ↗
What to watch
2029 (24)
January 2029 (2)
Phase 3Small Cell Lung CancerActive not recruiting
Est. primary completion 2029-01-04 · NCT07005128 · CT.gov ↗
What to watch
Phase 4Bladder CancerNot yet recruiting
Est. primary completion 2029-01-31 · NCT07876817 · CT.gov ↗
What to watch
February 2029 (3)
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2029-02 · NCT07149363 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2029-02-01 · NCT07339059 · CT.gov ↗
What to watch
Phase 1/2Small Cell Lung CancerRecruiting
Est. primary completion 2029-02-15 · NCT06780137 · CT.gov ↗
What to watch
March 2029 (1)
Phase 1Biliary Tract CancerRecruiting
Est. primary completion 2029-03 · NCT06564623 · CT.gov ↗
What to watch
April 2029 (1)
Phase 2Gastroesophageal AdenocarcinomaNot yet recruiting
Est. primary completion 2029-04 · NCT07625930 · CT.gov ↗
What to watch
May 2029 (1)
Phase 2Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8 …Recruiting
Est. primary completion 2029-05-25 · NCT06078709 · CT.gov ↗
What to watch
June 2029 (1)
Phase 3Small Cell Lung CancerActive not recruiting
Est. primary completion 2029-06-30 · NCT06992609 · CT.gov ↗
What to watch
July 2029 (4)
Phase 1/2Small Cell Lung CancerRecruiting
Est. primary completion 2029-07 · NCT07174583 · CT.gov ↗
What to watch
Phase 2/3Bladder CancerRecruiting
Est. primary completion 2029-07-21 · NCT06214572 · CT.gov ↗
What to watch
Phase 1/2Small Cell Lung CancerRecruiting
Est. primary completion 2029-07-25 · NCT06287775 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2029-07-31 · NCT07055581 · CT.gov ↗
What to watch
August 2029 (3)
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2029-08-04 · NCT07459634 · CT.gov ↗
What to watch
Phase 2HCC, Tace, ImmunotherapyNot yet recruiting
Est. primary completion 2029-08-14 · NCT07168668 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2029-08-31 · NCT03228667 · CT.gov ↗
What to watch
September 2029 (3)
Phase 1/2Biliary Tract CancerNot yet recruiting
Est. primary completion 2029-09 · NCT07269158 · CT.gov ↗
What to watch
Phase 2/3Hepatocellular CarcinomaRecruiting
Est. primary completion 2029-09-14 · NCT06904170 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-09-30 · NCT04892953 · CT.gov ↗
What to watch
October 2029 (3)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-10 · NCT06284317 · CT.gov ↗
What to watch
Phase 1/2Lung Cancer, Liver Cancer, Colorectal Cancer, Pancreas Cancer, Ovary Cancer, Head and Neck Cancer, Breast Cancer, Gastric Cancer …Recruiting
Est. primary completion 2029-10-30 · NCT05187338 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2029-10-31 · NCT05903092 · CT.gov ↗
What to watch
November 2029 (1)
Phase 3Gastric, Esophagogastric JunctionRecruiting
Est. primary completion 2029-11-01 · NCT07877818 · CT.gov ↗
What to watch
December 2029 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-12-31 · NCT06810609 · CT.gov ↗
What to watch
2030 (16)
January 2030 (3)
Phase 2Gastric CancerRecruiting
Est. primary completion 2030-01-01 · NCT07911280 · CT.gov ↗
What to watch
Phase 3Endometrial CancerRecruiting
Est. primary completion 2030-01-01 · NCT05255653 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2030-01-02 · NCT07122089 · CT.gov ↗
What to watch
February 2030 (1)
Phase 2Esophagogastric AdenocarcinomaNot yet recruiting
Est. primary completion 2030-02-01 · NCT07507968 · CT.gov ↗
What to watch
March 2030 (1)
Phase 2CLDN18.2-Positive Gastric Cancer, CLDN18.2-Positive Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2030-03-31 · NCT07872722 · CT.gov ↗
What to watch
April 2030 (3)
Phase 2Hepato Cellular CarcinomaRecruiting
Est. primary completion 2030-04-01 · NCT07489976 · CT.gov ↗
What to watch
Phase 1/2Folliculotropic Mycosis Fungoides, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides …Recruiting
Est. primary completion 2030-04-14 · NCT03011814 · CT.gov ↗
What to watch
Phase 2CancerRecruiting
Est. primary completion 2030-04-30 · NCT03847649 · CT.gov ↗
What to watch
May 2030 (4)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-05-28 · NCT05061550 · CT.gov ↗
What to watch
Phase 1Small Cell Lung CancerActive not recruiting
Est. primary completion 2030-05-30 · NCT05361395 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2030-05-31 · NCT06999707 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2030-05-31 · NCT06999694 · CT.gov ↗
What to watch
June 2030 (1)
Phase 1Biliary Tract CancerRecruiting
Est. primary completion 2030-06-30 · NCT07107750 · CT.gov ↗
What to watch
August 2030 (1)
Phase 1/2Hepatocellular CarcinomaRecruiting
Est. primary completion 2030-08-31 · NCT03942328 · CT.gov ↗
What to watch
December 2030 (2)
Phase 2Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer …Recruiting
Est. primary completion 2030-12 · NCT01042379 · CT.gov ↗
What to watch
Phase 2Resectable Intrahepatic CholangiocarcinomaNot yet recruiting
Est. primary completion 2030-12-10 · NCT07639528 · CT.gov ↗
What to watch
2031 (3)
June 2031 (1)
Phase 1Small Cell Lung CancerActive not recruiting
Est. primary completion 2031-06-23 · NCT06898957 · CT.gov ↗
What to watch
November 2031 (1)
Phase 2MPNST, NF1, SarcomaRecruiting
Est. primary completion 2031-11-15 · NCT05253131 · CT.gov ↗
What to watch
December 2031 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2031-12-30 · NCT07247786 · CT.gov ↗
What to watch
2032 (3)
May 2032 (1)
Phase 3Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma …Recruiting
Est. primary completion 2032-05-31 · NCT06058377 · CT.gov ↗
What to watch
July 2032 (1)
Phase 2Endometrial CancerActive not recruiting
Est. primary completion 2032-07-01 · NCT06680739 · CT.gov ↗
What to watch
August 2032 (1)
Phase 2Intrahepatic CholangiocarcinomaRecruiting
Est. primary completion 2032-08 · NCT07766187 · CT.gov ↗
What to watch
2033 (1)
January 2033 (1)
Phase 2Biliary Tract CancerNot yet recruiting
Est. primary completion 2033-01 · NCT07938645 · CT.gov ↗
What to watch
2039 (1)
July 2039 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2039-07-15 · NCT06498635 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

13 November 2026ApprovalFDA approves perioperative Imfinzi with neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer
US, FDA · Source ↗